IL10 and inflammatory bowel disease: Indeed, Fc receptor–mediated effects contribute to the therapeutic response to infliximab and adalimumab in mouse models of inflammatory bowel disease (IBD) (54), and patients with IBD only respond to full IgG1 anti-TNF therapies via macrophage IL-10 signaling (55–57).